Alex Chang, Ph.D., received his bachelor’s degree in biochemistry from Rutgers College, and completed his Ph.D. from the Graduate School of Biological Sciences at the Mount Sinai School of Medicine in New York. He started in the pharmaceutical industry with Hoffmann-La Roche in 1993 as a scientist in the Product Development arm of the Polymerase Chain Reaction Department. Upon completion of his doctoral degree, Alex moved to ImClone Systems as a Post-doctoral Fellow, working in the Molecular Biology department, where he focused on novel oncology targets and kidney cancer. Alex switched to the business development arena, and by 2009, ran the North America BD operations for Samyang Research Corp, a company headquartered in Seoul, South Korea; and was responsible for in-licensing NCE and biologic partnering activities, drug pipeline out-licensing projects, the assessment of drug delivery technologies, market and competitive analysis, and the management of the due diligence process. He was the lead for Samyang in managing their multimillion-dollar siRNA License and Research Collaboration Agreement with Takeda. In 2012, Alex furthered his multinational experience through a global role for Glenmark Pharmaceuticals, an India-based pharmaceutical company with sales over $1 billion USD. Alex’s primary responsibility was directing the business development activities for the Novel R&D segment of the Glenmark business focusing on a novel bispecific antibody drug platform, the oncology, and pain and inflammation therapeutic areas.

At KLOX Technologies Inc, Alex leads the business development and alliance management activities, and with partners Colgate Palmolive and LEO Pharma (see www.kleresca.com), the development and commercialization of products based on the novel science of biophotonics and photobiomodulation for diseases in dermatology, oral health and wound care. KLOX is entertaining partnership discussions in wound care.